PTC Therapeutics Inc (PTCT)
32.30
+1.24
(+3.99%)
USD |
NASDAQ |
May 10, 16:00
32.30
0.00 (0.00%)
After-Hours: 18:11
PTC Therapeutics Enterprise Value: 1.782B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 1.782B |
| May 08, 2024 | 1.788B |
| May 07, 2024 | 1.838B |
| May 06, 2024 | 1.928B |
| May 03, 2024 | 1.931B |
| May 02, 2024 | 1.978B |
| May 01, 2024 | 2.020B |
| April 30, 2024 | 1.866B |
| April 29, 2024 | 1.865B |
| April 26, 2024 | 1.591B |
| April 25, 2024 | 1.355B |
| April 24, 2024 | 1.333B |
| April 23, 2024 | 1.349B |
| April 22, 2024 | 1.392B |
| April 19, 2024 | 1.341B |
| April 18, 2024 | 1.292B |
| April 17, 2024 | 1.328B |
| April 16, 2024 | 1.338B |
| April 15, 2024 | 1.368B |
| April 12, 2024 | 1.425B |
| April 11, 2024 | 1.500B |
| April 10, 2024 | 1.462B |
| April 09, 2024 | 1.515B |
| April 08, 2024 | 1.460B |
| April 05, 2024 | 1.471B |
| Date | Value |
|---|---|
| April 04, 2024 | 1.532B |
| April 03, 2024 | 1.623B |
| April 02, 2024 | 1.577B |
| April 01, 2024 | 1.591B |
| March 31, 2024 | 1.630B |
| March 28, 2024 | 3.450B |
| March 27, 2024 | 3.477B |
| March 26, 2024 | 3.364B |
| March 25, 2024 | 3.432B |
| March 22, 2024 | 3.450B |
| March 21, 2024 | 3.533B |
| March 20, 2024 | 3.482B |
| March 19, 2024 | 3.553B |
| March 18, 2024 | 3.444B |
| March 15, 2024 | 3.485B |
| March 14, 2024 | 3.435B |
| March 13, 2024 | 3.580B |
| March 12, 2024 | 3.649B |
| March 11, 2024 | 3.573B |
| March 08, 2024 | 3.609B |
| March 07, 2024 | 3.578B |
| March 06, 2024 | 3.587B |
| March 05, 2024 | 3.619B |
| March 04, 2024 | 3.595B |
| March 01, 2024 | 3.669B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.292B
Minimum
Apr 18 2024
4.670B
Maximum
May 22 2023
2.829B
Average
2.769B
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 12.35B |
| Pfizer Inc | 216.74B |
| Catalyst Pharmaceuticals Inc | 1.539B |
| Geron Corp | 1.947B |
| Perspective Therapeutics Inc | 1.049B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.58M |
| Revenue (Quarterly) | 210.12M |
| Total Expenses (Quarterly) | 255.67M |
| EPS Diluted (Quarterly) | -1.20 |
| Gross Profit Margin (Quarterly) | 92.98% |
| Profit Margin (Quarterly) | -43.58% |
| Earnings Yield | -23.78% |
| Normalized Earnings Yield | -15.16 |